Scientists Achieve Robust Repair Of Injured Heart Muscle eMaxHealth.com, NC - Specifically, myoendothelial cells show potential as a therapy for people who have suffered a myocardial infarction," said Dr. Huard, also the Henry J. ...
Stem Cell Research in Cardiology - Report Available Now MarketWatch - Nov 14, 2008 Heart disease, including myocardial infarction and ischemia, can be treated with the applications of stem cells. The concept of stem cell transplantation to ...
Athersys, Inc. Q3 2008 Earnings Call Transcript Seeking Alpha, NY - Nov 27, 2008 In the first of these MultiStem is administered to patients that have suffered an acute myocardial infarction or heart attack. ...ATHX
Capricor Announces Preclinical Results MarketWatch - Nov 11, 2008 CPI-003, Capricor's lead product candidate, is an autologous adult stem cell product for the treatment of myocardial infarction. ...
The legacy of coronary sinus interventions: Endogenous ... The Journal of Thoracic and Cardiovascular Surgery - Nov 24, 2008 The clinical potential of PICSO also extends as adjunct therapy in acute myocardial infarction in revascularization procedures by limiting myocardial...
Capricor Announces Preclinical Results International Business Times, NY - Nov 11, 2008 CPI-003, Capricor's lead product candidate, is an autologous adult stemcell product for the treatment of myocardial infarction. The productcontains multiple ...
Reactivation of Cytomegalovirus Infection in Critically Ill ... Journal of American Medical Association (subscription), IL - Nov 25, 2008 First, the authors combined many different patient populations into the category of "critical illness," ranging from acute myocardial infarction to burn ...
Source: Google News
Recent News and Articles on the Keywords: cells + 0.33 + 125,000 Related to the article below (Last Update: 8/7/2008)
OXiGENE Reports Second Quarter 2008 Results FOXBusiness - Aug 4, 2008 Through interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving ...OXGN - OTC:CMTX
Fermented Food Products Containing Probiotic Strains FLEXNEWS, France - Jul 25, 2008 C. temperature Survival of Waiting time for 0.33 h 1 h 2.5 h the smoothing at the end bifidobacteria of the fermentation Cooling temperature 15.degree. ...SAU:2100
SunPower Reports Record Second-Quarter 2008 Results PR Newswire (press release), NY - Jul 17, 2008 SunPower high-efficiency solar cells and solar panels generate up to 50 percent more power than conventional solar technologies and have a uniquely ...SPWR - CY
Effects of charged amphiphiles on cardiac cell contractility are mediated via effects on Ca2+ … - JA Post, S Ji, KS Leonards, GA Langer - American Journal of Physiology- Heart and Circulatory …, 1991 - Am Physiological Soc ... (in mM) 136 NaCl, 9 NaOH, 0.33 NaH2P04, 5.4 KCl, 1.0 ... level of Ca2+ in adult rabbit
mvocardial cells. ... 128000 127000 126000 125000 124000 0 20 40 60 Time (min) ...
Initial steps in the degradation of n-alkane-1-sulphonates by Pseudomonas - GJE Thysse, TH Wanders - Antonie van Leeuwenhoek, 1974 - Springer ...125000 g extracts of octanesulfonate-grown Ps.AJ 2 cells with ... of octane-l-sulfonate-
grown Pseudomonas AJ 2 cells Enzyme substrate ... 6-hydroxyhexane 0.33 0 none ...
The Hydrogen-Activating Enzymes of the Cells - T Thunberg - The Quarterly Review of Biology, 1930 - JSTOR ... alkaline solutions to about 0.02 millimolar (= 1:125000). ... requires for decoloration
only 0.33 microgram of ... HYDROGEN-ACTIVATING ENZYMES OF CELLS 341 and fluids ...
Membrane lipids of Mycoplasma fermentans - M Salman, I Deutsch, M Tarshis, Y Naot, S Rottem - FEMS Microbiology Letters, 1994 - Blackwell Synergy ... Rf = 0.23), phosphatidylcholine (Rf = 0.33), phosphatidyl- glycerol (Rf ...cells,
facilitating their fusion with host cells. ... 1 : 12500 0.7 1172 1 : 125000 0.07 422 ...
Natural convection mass transfer at spheres - GH Sedahmed, IAS Mansour, TH El-Sherify, A Khalaf … - Journal of Applied Electrochemistry, 1984 - Springer ... I I 0.5 1.0 Cell X X ... Again the exponent 0.33 in Equation 6 reveals a turbulent flow
mechanism, this is consistent with the ... 8 2.10 14.44 300 8.128 X 104 125000...
Source: Google Scholar
Myocardial infarction: stem cells lead to a reduction of the infarct
Researchers at the Catholic University of Leuven, connected with the University Hospital - Gasthuisberg, the Stem Cell Institute Leuven ( SCIL ), and the Flanders Interuniversity Institute for Biotechnology ( VIB ), have shown that the administration of a patient's own stem cells has a significant positive effect on the heart's recovery: in the patients studied, the size of the infarct was clearly reduced.
The use of stem cells appears to be safe, and to date no side effects have occurred that can be attributed to the stem cells.
This study is published in The Lancet.
In an acute myocardial infarction, the flow of blood from a blood vessel in the heart is blocked, whereby the cardiac muscle receives insufficient oxygen and heart tissue dies.
In many cases, the supply of blood in the deadened portion of the heart can be restored via the so-called balloon technique. But the heart suffers permanent damage, primarily to the left ventricle.
The researchers in Leuven have tested the administration of bone marrow stem cells on patients stricken with acute myocardial infarction.
In the 67 patients of the study, the supply of blood in the heart was restored optimally via the balloon technique. Then, within 24 hours, some patients received an injection of stem cells from their own bone marrow and some received placebo.
Improvement in the global functioning of the left ventricle was comparable in both the control group ( injected with the placebo ) and the group that received the stem cells. But a clear global improvement in function was found in the sub-group of patients who had been afflicted with the most serious infarctions.
Moreover, the reduction of the size of infarct was significantly greater in all patients in the 'stem cell group' and correlates with a better preserved regional left ventricle function.
It is still much too early to conclude that every patient with a myocardial infarction should be treated with stem cells. Indeed, there is still a long road to travel in the development of a medication, and no risks must be taken along the way.
Source: VIB, Flanders Interuniversity Institute of Biotechnology, 2006
